Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The post hoc analysis of the STEP programme reported depressive symptoms in 2.8% of semaglutide patients against 4.1% on placeboa figure that looks reassuring until you notice the population was mostly nondiabetic and on subcutaneous 2.4 mg, which tells us nothing about lower doses of the oral drug in people with T2DM ( The FAERS signal (a reporting odds ratio of 1.87 for depression) and the adjusted ratio of 1.70 for depressed mood disorders from VigiBase both fit a risk that shows up at the level of the individual patient, even when the randomised trials, looking at groups, do not see it ( A propensity-matched cohort study in 162,253 patients found a 195% higher risk of major depression with GLP-1 RA treatment compared with matched controls ( 5.5 Clinical implications A few practical lessons come out of this case
Similar content being viewed by others Subjects Main Glucagon-like peptide-1 (GLP-1) analogs and DPPIV inhibitors are increasingly used long term in patients with diabetes mellitus worldwide
Lastly, the mTOR-S6K pathway was explored by detecting the protein expression of S6K and phosphorylated S6K
It was a primary finding from a dedicated liver trial published in Nature Medicine
:
US$ 29.65
US$ 25.43
US$ 28.04
US$ 26.52
US$ 22.37
US$ 25.84
US$ 27.25
US$ 23.33
US$ 22.92
US$ 26.90
US$ 27.31
US$ 24.78
US$ 28.00
